Archive for 'News'

Jun 08

Apogee is pleased to announce GMP capsule production for the Phase I clinical trial in solid tumors has been successfully completed. 

The IND package is currently being assembled for a  submission to the FDA, targeted for the  3rd quarter of 2010.

May 15

Apogee is pleased to announce a publication in “Investigational New Drugs” (abstract) that shows the synergy between ABC294640 and sorafenib in inhibiting tumor growth in animal models.

Dr. Lynn Maines of Apogee stated  “We have seen this synergism with ABC294640 and several other drugs that our currently the standard of care for various cancers as well as inflammatory diseases.  ABC294640 looks very promising not only as a stand alone agent but as an add on to current therapies due to its low toxicity and the several proliferative and inflammatory cascades it negatively influences in cancer and inflammation.”

Feb 01

This important article is being published in Journal of Pharmacology and Experimental Therapeutics (abstract) and describes the promising pharmaceutical properties of the lead compound, ABC294640.

Dr. Charles D. Smith, President and CEO of Apogee, stated the company is pleased to publish this important information in such a respected and high impact journal.  He believes it further validates the science and the importance of Apogee’s novel sphingosine kinase inhibitor program.

Jan 25

In anticipation of filing an IND for solid tumor cancers later this year, Apogee presented a poster entitled “Combined Anticancer Effects of a Sphingosine Kinase Inhibitor and Sorafenib” at the 2010 ASCO Gastrointestinal Cancers Symposium recently held in Orlando, FL.

Dr. Charles Smith, President and CEO presented for the company and was pleased with the positive feedback and collaborative opportunities that opened up during the meeting.

Mar 14

Apogee Biotechnology Corporation has received a Phase II Small Business Innovation Research grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

This award, in the amount of nearly $1 million, will fund the preclinical studies of the sphingosine kinase inhibitor platform in models of rheumatoid arthritis and osteoarthritis.

Mar 05

Apogee is pleased to announce the issuance of U.S. patent #7,338,961, entitled “Sphingosine kinase inhibitors.”

This patent is the first issue in a series of domestic and international filings protecting Apogee’s sphingosine kinase inhibitor program.  Importantly, this patent specifically protects the lead compound of development, ABC294640, and related chemotypes.

Jun 20

Apogee Biotechnology Corporation has recently been awarded research grants from two prestigious institutions.

The first grant, a Phase II Small Business Innovation Research grant, is from the National Eye Institute.

This grant, in the amount of $1.9 million, will fund preclinical studies of Apogee’s sphingosine kinase inhibitor platform in models of retinopathy.

The second grant, a Phase II Small Business Innovation Research grant, is awarded from the National Institute of Diabetes and Digestive and Kidney Diseases.

This award, in the amount of $1.7 million dollars, will fund the preclinical development of Apogee’s sphingosine kinase inhibitor platform toward clinical trials in ulcerative colitis.

Feb 19

Apogee Biotechnology Corporation is now the first tenant in the technology suites of the Hershey Center for Applied Research.

Apogee is relocating into this new, state-of-the-art facility and expanding its laboratory space signficantly.

Ongoing collaborations with several professors at the Pennsylvania State College of Medicine in Hershey will be facilitated, especially with the Pharmacology Department, which is located on the third floor of the building.

Dr. Lynn Maines, Vice President of Research and Business Affairs for Apogee, said “It is valuable to us to be able to share the expertise and the resources of such a great medical research institution like Penn State.  It allows us to take on more research projects that would be much more difficult, or not possible, without them.”

Apogee’s new address is 1214 Research Boulevard, Suite 1016, Hummelstown, PA 17036.